Clinical Trial

A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 20, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to learn about the effectiveness of Nivolumab in combination with chemotherapy as Neoadjuvant therapy for patients with non-small cell lung cancer (NSCLC). The main question it aims to answer is: Does patient with NSCLC in treatment of Nivolumab combined with chemotherapy demonstrate better pCR and PFS ? Is it safe for patient with NSCLC in treatment of Nivolumab combined with chemotherapy ? The data for those participants already receiving nivolumab in combination with chemotherapy as part of their regular medical care for NSCLC will be collected within the designated collection period.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-09.
Status change: Not Yet Recruiting → Recruiting 2026-05-18
Trial Details
NCT Number NCT07169708
Lead Sponsor Ono Pharmaceutical Co., Ltd.
Collaborators: Bristol-Myers Squibb
Conditions Non Small Cell Lung Cancer NSCLC
Enrollment 100 participants
Start Date 2026-03-20
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-20